UBS AM’s Endocyte, Inc. Common Stock ECYT Stock Holding History

UBS AM’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-27,500	Closed	-$488K	–	2857
2018 Q3	$488K	Sell	27,500 -2,000	-7%	-$34.3K	﹤0.01%	2092
2018 Q2	$407K	Buy	+29,500	New	+$350K	﹤0.01%	2186
2015 Q4	–	Sell	-33,899	Closed	-$155K	–	2732
2015 Q3	$155K	Hold	33,899	–	–	﹤0.01%	2548
2015 Q2	$176K	Hold	33,899	–	–	﹤0.01%	2614
2015 Q1	$212K	Hold	33,899	–	–	﹤0.01%	2462
2014 Q4	$213K	Buy	+33,899	New	+$207K	﹤0.01%	2441
2014 Q2	–	Sell	-435,060	Closed	-$10.4M	–	2602
2014 Q1	$10.4M	Sell	435,060 -132,000	-23%	-$1.91M	0.01%	837
2013 Q4	$6.06M	Buy	+567,060	New	+$6.26M	0.01%	963

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $830M AUM 21.8% 1-Year Est. Return

UBS AM's ECYT Position: Q4 2018 in Review

UBS AM sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 27,500 shares — an estimated $488K sold.

UBS AM first reported a position in ECYT in Q4 2013 and held it in 8 quarters. The position peaked at $10.4M in Q1 2014. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

UBS AM reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
UBS AM sold 27,500 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $488K.
UBS AM first reported a position in Endocyte, Inc. Common Stock in Q4 2013 and held it in 8 quarters.
UBS AM's Endocyte, Inc. Common Stock position peaked at $10.4M in Q1 2014.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on UBS AM's 13F filing for Q4 2018, filed 13 Feb 2019.